Century Therapeutics, Inc. (IPSC) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $18.00K; Additional Paid in Capital, Common StockUSD $1.08B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-694.00K; Retained Earnings (Accumulated Deficit)USD $-848.11M.
- 2026-03-31: Common Stock, Value, IssuedUSD $18.00K; Additional Paid in Capital, Common StockUSD $1.08B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-585.00K; Retained Earnings (Accumulated Deficit)USD $-813.56M.
- 2025-12-31: Common Stock, Value, IssuedUSD $9.00K; Additional Paid in Capital, Common StockUSD $950.81M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $30.00K; Retained Earnings (Accumulated Deficit)USD $-791.92M.
- 2025-09-30: Common Stock, Value, IssuedUSD $9.00K; Additional Paid in Capital, Common StockUSD $949.01M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $64.00K; Retained Earnings (Accumulated Deficit)USD $-772.74M.
Century Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $18.00K | $1.08B | $-694.00K | $-848.11M | $232.34M | 3 month · $37.00K | 3 month · $1.95M | (m) |
| 2026-03-31 | $18.00K | $1.08B | $-585.00K | $-813.56M | $264.74M | (m) | 3 month · $1.45M | (m) |
| 2025-12-31 | $9.00K | $950.81M | $30.00K | $-791.92M | $158.94M | (m) | 12 month · $6.84M | (m) |
| 2025-09-30 | $9.00K | $949.01M | $64.00K | $-772.74M | $176.35M | (m) | 3 month · $891.00K | (m) |
| 2025-06-30 | $9.00K | $948.12M | $83.00K | $-738.32M | $209.90M | (m) | 3 month · $2.22M | (m) |
| 2025-03-31 | $9.00K | $945.90M | $305.00K | $-705.78M | $240.44M | (m) | 3 month · $2.43M | (m) |
| 2024-12-31 | $9.00K | $943.37M | $324.00K | $-782.34M | $161.36M | (m) | 12 month · $12.69M | (m) |
| 2024-09-30 | $9.00K | $941.18M | $758.00K | $-746.27M | $195.69M | (m) | 3 month · $3.32M | (m) |
| 2024-06-30 | $8.00K | $937.45M | $-309.00K | $-715.04M | $222.10M | (m) | 3 month · $3.50M | (m) |
| 2024-03-31 | $6.00K | $861.95M | $-241.00K | $-683.83M | $177.88M | (m) | 3 month · $3.21M | (m) |
| 2023-12-31 | $6.00K | $840.41M | $108.00K | $-655.77M | $184.75M | (m) | 12 month · $14.62M | (m) |
| 2023-09-30 | $6.00K | $836.90M | $-1.30M | $-616.37M | $219.23M | (m) | 3 month · $3.98M | (m) |
| 2023-06-30 | $6.00K | $832.42M | $-1.21M | $-583.65M | $247.57M | (m) | 3 month · $3.29M | (m) |
| 2023-03-31 | $6.00K | $828.81M | $-1.27M | $-550.36M | $277.18M | (m) | 3 month · $3.80M | (m) |
| 2022-12-31 | $6.00K | $824.29M | $-2.46M | $-519.10M | $302.74M | (m) | 12 month · $10.67M | (m) |
| 2022-09-30 | $6.00K | $821.22M | $-3.60M | $-487.42M | $330.20M | (m) | 3 month · $2.79M | (m) |
| 2022-06-30 | $6.00K | $818.05M | $-3.43M | $-456.67M | $357.95M | (m) | 3 month · $2.77M | (m) |
| 2022-03-31 | $6.00K | $814.98M | $-2.64M | $-425.68M | $386.66M | (m) | 3 month · $2.38M | (m) |
| 2021-12-31 | $5.00K | $785.05M | $-650.00K | $-388.17M | $396.24M | (m) | 12 month · $4.66M | 12 month · $69.00K |
| 2021-09-30 | $5.00K | $783.02M | $-63.00K | $-359.97M | $422.99M | (m) | 3 month · $1.22M | (m) |
| 2021-06-30 | $5.00K | $781.56M | $-3.00K | $-333.96M | $447.60M | (m) | 3 month · $1.71M | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | $-91.56M | (m) | 3 month · $95.00K | (m) |
| 2020-12-31 | $1.00K | $217.83M | $-3.00K | $-292.34M | $-106.41M | (m) | 12 month · $876.00K | 12 month · $46.00K |
| 2020-09-30 | (m) | (m) | (m) | (m) | $-129.31M | (m) | 3 month · $144.00K | 3 month · $46.00K |
| 2020-06-30 | (m) | (m) | (m) | (m) | $-116.35M | (m) | 3 month · $137.00K | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | $-101.28M | (m) | 3 month · $221.00K | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | $-91.86M | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |